Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

76.79 -1.08 (-1.39%)

Streaming Delayed Price Updated: 1:53 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

Topics Economy Intellectual Property

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Topics Economy Intellectual Property Stocks

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Earnings Outlook For BridgeBio Pharma ↗

October 28, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

Via Investor's Business Daily

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss ↗

October 29, 2025

BridgeBio Pharma's Q3 2025 earnings show a major revenue beat driven by Attruby sales, but a widened quarterly loss led to a negative market reaction.

Via Chartmill

BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder ↗

October 29, 2025

BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EMA submissions in 2026.

Via Benzinga

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗

October 29, 2025

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

Via Stocktwits

BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High ↗

October 29, 2025

A second positive "domino" fell for BridgeBio on Wednesday after the company reported promising results in a genetic disease.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 28, 2025

Via Benzinga

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗

October 27, 2025

Via Benzinga

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial ↗

October 27, 2025

BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026.

Via Stocktwits

BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition ↗

September 29, 2025

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.

Via Benzinga

BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival ↗

September 28, 2025

The company ran an exploratory analysis of its drug, Attruby, in patients with cardiomyopathy due to TTR amyloidosis.

Via Investor's Business Daily

BridgeBio Pharma Inc (NASDAQ:BBIO) Shows Strong Technical Setup for Potential Breakout ↗

September 22, 2025

BridgeBio Pharma (BBIO) shows strong technicals with a perfect 10 rating. Currently in a consolidation pattern, it may be poised for a breakout above resistance, offering a potential entry for...

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2025

Via Benzinga

BRIDGEBIO PHARMA INC (NASDAQ:BBIO) Shows Strong Technical Breakout Potential with High Momentum and Consolidation Setup ↗

August 12, 2025

BridgeBio Pharma (BBIO) shows strong breakout potential with a perfect Technical Rating of 10 and Setup Rating of 9, signaling robust momentum and consolidation. Ideal for traders eyeing...

Via Chartmill

BridgeBio Pharma Inc (NASDAQ:BBIO) Shares Drop 11% After Q2 2025 Earnings Miss Despite Revenue Beat ↗

August 05, 2025

BridgeBio Pharma reports mixed Q2 2025 results with revenue beating estimates but EPS missing, causing an 11% stock drop. Strong prescription growth contrasts with profitability concerns.

Via Chartmill

Topics Earnings

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 15, 2025

Via Benzinga

Is Pfizer Stock a Yield Trap? ↗

July 03, 2025

Via The Motley Fool

Topics Intellectual Property

Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis ↗

June 05, 2025

Via The Motley Fool

Topics Intellectual Property Retirement

The Smart Money Is Buying These 10 Stocks ↗

May 20, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.